Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

STAT3 Inhibitor for Solid Tumors

This study has been completed.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: August 7, 2009
Last updated: February 11, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2012
  Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):